To be clear, almost all of these studies showed very small effect sizes. The best therapeutics we have are remdesevir (small but real effect on severity, unclear effect on hospitalization and death), dexamethosone (moderate to large effect on death when hospitalized), and antibody drugs for which Lilly’s has already been remove because ineffective against variants though Regeneron’s cocktail seems quite good. Fluvoxamine is I’m sure under investigation, we’ll get a readout eventually but that’s a relatively new result.

The best drugs we have are either:

1.) treat the virus with a novel entity (Regeneron, the other antibodies)

2.) treat the inflammation (dexamethosone, possibly eventually fluvoxamine)

The repurposing and general antivirals (including remdesevir) have little effect and likely won’t make a difference. There are novel drugs being developed (Pfizer just started a protease inhibitor trial) but that’s the only place I’d expect to see real impact, with fluvoxamine as a treat the symptoms wildcard. People have been trying to find drugs or repurpose, and academic medical centers have been working on it. It’s that almost nothing works when subjected to the hard trials.